Trials / Completed
CompletedNCT05181085
Study of NST-6179 in Healthy Subjects
A Phase 1, First Time in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NST 6179 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- NorthSea Therapeutics B.V. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
A double-blind, randomized, placebo controlled, single and multiple oral dose study to assess safety and tolerability of single and multiple doses of NST-6179 in healthy male and female subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NST 6179 | orally administered, fully synthetic medium chain fatty acid (MCFA) analogue |
| DRUG | Placebo | inactive analogue |
Timeline
- Start date
- 2021-11-11
- Primary completion
- 2022-05-27
- Completion
- 2022-05-27
- First posted
- 2022-01-06
- Last updated
- 2024-06-24
- Results posted
- 2024-06-24
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05181085. Inclusion in this directory is not an endorsement.